Lecanemab and Donanemab After 1 Year: Early Lessons
Summary
German memory clinics report no new safety signals with lecanemab and donanemab, while clinicians stress patient selection, MRI monitoring, and treatment early in disease. Medscape News Europe
Description from Medscape.
Who is covering this
-
Lecanemab and Donanemab After 1 Year: Early Lessons
German memory clinics report no new safety signals with lecanemab and donanemab, while clinicians stress patient selection, MRI monitoring, and treatment early in disease. Medscape News Europe
Comments
Comments need JavaScript.